ADMA NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

ADMA Biologics Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 8.46 USD
2.3% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -27.2% below the Trend Line and sits at 9.4% of its 52-week range. The latest completed week returned 2.3%, after a -5.5% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 34/100 conviction, while the latest news-sentiment score is 37/100. Near-term considerations: volume confirmation is below normal; earnings are due in 3d.

Setup score 25 out of 100
Latest Close 8.46 USD 31 Jul 2026
1W Return 2.3% latest completed week
4W Return -5.5% short-term follow-through
12W Return 3.5% quarterly tape
Trend Breadth 7.7% 4 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 2.3% Latest completed week; four-week move -5.5%. Indicator stack 4/63 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 34/100 conviction; expected move 17.1%. News sentiment 37/100 59 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -27.2% below the Trend Line and sits at 9.4% of its 52-week range. The latest completed week returned 2.3%, after a -5.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0412-week average 0.02

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.04Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -5.5% over four weeks, 3.5% over 12 weeks, and -56.2% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W2.3%
4W-5.5%
12W3.5%
26W-51.1%
52W-56.2%
Active trend streak0 weeks
Active weeks in one year4
Trend breadth7.7%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.12Latest activity-pressure read.
Pressure change135.4%Four-week change in activity pressure.
Leadership-44.99Latest relative-leadership reading.
RS change5.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 97% Model confidence 93%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength70/100Blend of value, momentum, and quality. Underlying universe rank 31; rank 1 is best.
Value71/100Relative valuation strength. Underlying universe rank 30; rank 1 is best.
Quality89/100Profitability and accounting quality. Underlying universe rank 12; rank 1 is best.
Momentum5/100Medium-term price momentum. Underlying universe rank 96; rank 1 is best.
Growth29/100Revenue and earnings growth. Underlying universe rank 72; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework88/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
11.6x
Price divided by trailing earnings.
Price / sales
3.8x
Market value relative to trailing revenue.
EV / EBITDA
9.0x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
7.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
61.3%
Gross profit retained from each unit of revenue.
Operating margin
41.9%
Operating profit retained from revenue.
Free-cash-flow margin
29.2%
Free cash flow generated from revenue.
Return on invested capital
37.5%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
11.0%
Latest one-year revenue growth.
EPS growth
-20.0%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
33.0%
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
1.5%
Net share repurchases relative to market value.
Shareholder yield
1.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

ADMA shows bullish options pressure with a 34/100 conviction score, put-call volume ratio of 0.43, expected move of 17.1%, and Sharemaestro trend signal inactive.

Conviction34/100
Expected move17.1%
Put/call volume0.43
Pressure48
Speculation8
Volatility95
Trend agreement9
Open options detail
Insider activity5 / 0

5 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment37/100

Weighted news tone is negative across 59 relevant articles.

8 positive · 27 neutral · 24 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move17.1%Nearest-chain priced movement where available.
52-week drawdown-58.6%Distance below the 52-week high.
13-week volatility6.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+13.5%Week of 17 Apr.
Worst week-35.4%Week of 27 Mar.
Latest week+2.3%Week of 31 Jul.

Shape of recent returns

Strong gains3
Modest gains8
Flat weeks0
Modest losses8
Sharp losses7
Recent vol6.7%13-week weekly-return volatility.
Base vol7.5%52-week weekly-return volatility.
Up/down split21/31Count of positive and negative weeks in the 52-week window.
Average skew4.3% / -5.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape23/100

Trend, activity pressure, participation, and risk combine to a 23/100 tape read.

 Indicator analysis14/100

Latest 12-week confirmation: trend 0/12, activity pressure 3/12, relative leadership 0/12.

Activity pressure 0.04; No reversal markers Factors60/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 27; Small Cap Core rank 69 SVQF88/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 89.0 of 726 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options41/100

ADMA shows bullish options pressure with a 34/100 conviction score, put-call volume ratio of 0.43, expected move of 17.1%, and Sharemaestro trend signal inactive.

Bullish · Call-side pressure · Expected move 17.1% Sentiment37/100

Weighted news tone is negative across 59 relevant articles.

Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note Insiders5 / 0

5 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings3d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20268.46 USD2.3%11.62 USD12.89 USD0.12-44.999.7MOff
24 Jul 20268.27 USD-5.1%11.94 USD12.86 USD0.19-46.9712.0MOff
17 Jul 20268.71 USD-4.1%12.30 USD12.83 USD0.19-45.9416.1MOff
10 Jul 20269.08 USD1.5%12.66 USD12.80 USD-0.03-46.7611.6MOff
3 Jul 20268.95 USD2.3%13.02 USD12.76 USD-0.33-47.4714.5MOff
26 Jun 20268.75 USD5.3%13.38 USD12.73 USD-0.67-49.0419.4MOff
19 Jun 20268.31 USD1.2%13.73 USD12.70 USD-0.94-54.5320.1MOff
12 Jun 20268.21 USD3.0%14.03 USD12.67 USD-1.10-54.6817.5MOff
5 Jun 20267.97 USD-0.1%14.27 USD12.64 USD-1.17-55.9414.4MOff
29 May 20267.98 USD-3.2%14.49 USD12.61 USD-1.11-58.7312.8MOff
22 May 20268.24 USD-0.4%14.74 USD12.59 USD-1.05-57.0217.3MOff
15 May 20268.27 USD1.2%14.97 USD12.56 USD-0.98-57.2328.1MOff
8 May 20268.17 USD-22.3%15.18 USD12.54 USD-0.92-58.6467.3MOff
1 May 202610.52 USD-6.6%15.39 USD12.51 USD-1.03-44.9525.0MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.